We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals

98 hedge funds and large institutions have $483M invested in Rhythm Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $154K | Put options by funds: $90K

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

1% more funds holding

Funds holding: 9798 (+1)

8% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 12

0.91% more ownership

Funds ownership: 95.47%96.39% (+0.91%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

23% less capital invested

Capital invested by funds: $626M → $483M (-$142M)

Holders
98
Holders Change
+1
Holders Change %
+1.03%
% of All Funds
1.51%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
39
Reduced
29
Closed
12
Calls
$154K
Puts
$90K
Net Calls
+$64K
Net Calls Change
-$387K

RYTM Hedge Fund Activity: Q4 2021 in Review

98 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2021, worth a combined $483M — down 23% from $626M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new RYTM positions and 12 closed out — a net gain of 1 holder — while 39 added to existing stakes and 29 trimmed.

The largest buyer was Franklin Resources, adding an estimated $15.4M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $19.5M sold.

  • 98 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2021, up from 97 in Q3 2021.
  • Funds reported $483M of Rhythm Pharmaceuticals stock for Q4 2021, down 23% quarter-over-quarter.
  • 13 funds opened new Rhythm Pharmaceuticals positions in Q4 2021 and 12 closed out, a net change of +1 holder.
  • The largest Rhythm Pharmaceuticals buyer in Q4 2021 was Franklin Resources, an estimated $15.4M added.
  • The largest Rhythm Pharmaceuticals seller in Q4 2021 was Gilder Gagnon Howe & Co, an estimated $19.5M sold.

Based on aggregated 13F filings for Q4 2021.